Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus

References

• Charvat H, Goto A, Goto M, et al. Impact of population aging on trends in diabetes prevalence: a meta-regression analysis of 160,000 Japanese adults. J Diabetes Investig. 2015;6:533–542.
   PubMed Web of Science ®Google Scholar
• Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig. 2016;7(Suppl 1):102–109.
   PubMed Web of Science ®Google Scholar
• Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696–708.
   PubMed Web of Science ®Google Scholar
• Park H, Park C, Kim Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012;46:1453–1469.
   PubMed Web of Science ®Google Scholar
• Cho YM. Incretin physiology and pathophysiology from an Asian perspective. J Diabetes Investig. 2015;6:495–507.
   PubMed Web of Science ®Google Scholar
• Moller JB, Pedersen M, Tanaka H, et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care. 2014;37:796–804.
   PubMed Web of Science ®Google Scholar
• Hinnen D. Dipeptidyl peptidase-4 inhibitors in diverse patient populations with type 2 diabetes. Diabetes Educ. 2015;41:19S–31S.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14:505–524.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Montilla S, Marchesini G, Sammarco A, et al. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutr Metab Cardiovasc Dis. 2014;24:1346–1353.
   PubMed Web of Science ®Google Scholar
• Sportiello L, Rafaniello C, Scavone C, et al. The importance of pharmacovigilance for the drug safety: focus on cardiovascular profile of incretin-based therapy. Int J Cardiol. 2016;202:731–735.
   PubMed Web of Science ®Google Scholar
• Yuasa S, Sato K, Takai M, et al. Factor analysis of changes in hemoglobin A1c after 12 months of sitagliptin therapy in patients with type 2 diabetes. J Clin Med Res. 2016;8:461–471.
   PubMedGoogle Scholar
• Umezawa S, Kubota A, Maeda H, et al. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: post hoc analysis of the ASSET-K study. BMC Endocr Disord. 2015;15:34.
   PubMed Web of Science ®Google Scholar
• Kanatsuka A, Sato Y, Kawai K, et al. Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38). J Diabetes Investig. 2016;7:386–395.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Marubayashi F, Yokota S, et al. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two phase III clinical studies. Expert Opin Pharmacother. 2015;16:971–981.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4:576–584.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K, Sasaki N, et al. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period. Expert Opin Pharmacother. 2017;18:1291–1300.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Inagaki N, Kondo K, et al. Efficacy and safety of teneligliptin added onto canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicentre, randomised, double-blind, placebo-controlled, parallel-group comparative study. Diabetes Obes Metab. 2017 Aug 8. DOI:10.1111/dom.13079
   Web of Science ®Google Scholar
• Fujihara K, Igarashi R, Matsunaga S, et al. Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42). Medicine (Baltimore). 2017;96:e6122.
   PubMed Web of Science ®Google Scholar
• Tenelia® 20 mg Tablets 2016 interview form. cited 2017 Oct 10. Available from: https://medical.mt-pharma.co.jp/di/file/if/tnl.pdf
   Google Scholar
• TENELIA® 20 mg tablets package insert. cited 2017 Oct 10. Available from: https://medical.mt-pharma.co.jp/di/file/dc/tnl.pdf
   Google Scholar
• JANUVIA® 12.5mg, 25mg, 50mg, 100mg tablets package insert. cited 2017 Oct 10. Available from: http://www.info.pmda.go.jp/downfiles/ph/PDF/170050_3969010F1034_2_27.pdf
   Google Scholar
• Equa® 50mg tablets package insert. cited 2017 Oct 10. Available from: www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/300242_3969011F1020_1_21#page=1
   Google Scholar
• Pharmaceuticals and Medical Devices Agency. Pharmaceuticals and medical devices safety information: alogliptin benzoate 2012. cited 2017 Oct 10. Available from: https://www.pmda.go.jp/files/000153459.pdf
   Google Scholar
• Pharmaceuticals and Medical Devices Agency. Summary of investigation results: linagliptin 2015. cited 2017 Oct 10. Available from: https://www.pmda.go.jp/files/000197853.pdf
   Google Scholar
• Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabetes Investig. 2014;5:475–477.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Managing older people with type 2 diabetes. cited 2017 Oct 10. Available from: https://www.ifa-fiv.org/wp-content/uploads/2014/02/IDF-Guideline-for-Older-People.pdf
   Google Scholar
• Bremer JP, Jauch-Chara K, Hallschmid M, et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513–1517.
   PubMed Web of Science ®Google Scholar
• Bruderer SG, Bodmer M, Jick SS, et al. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK-a nested case-control analysis. Diabetes Obes Metab. 2014;16:801–811.
   PubMed Web of Science ®Google Scholar
• Japan Diabetes Society (JDS)/Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with Diabetes, Haneda M, Ito H. Glycemic targets for elderly patients with diabetes. Diabetol Int. 2016;7:331–333. doi:10.1007/s13340-016-0293-8
   PubMed Web of Science ®Google Scholar
• Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27:1049–1058.
   PubMed Web of Science ®Google Scholar
• Bethel MA, Engel SS, Green JB, et al. Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes Care. 2017;40:494–501.
   PubMed Web of Science ®Google Scholar
• Barnett AH, Huisman H, Jones R, et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1413–1423.
   PubMed Web of Science ®Google Scholar
• Karyekar CS, Ravichandran S, Allen E, et al. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged >/= 65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging. 2013;8:419–430.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013;15:906–914.
   PubMed Web of Science ®Google Scholar
• Strain WD, Lukashevich V, Kothny W, et al. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013;382:409–416.
   PubMed Web of Science ®Google Scholar
• Monami M, Cremasco F, Lamanna C, et al. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011;27:362–372.
   PubMed Web of Science ®Google Scholar
• Goda M, Kadowaki T. Teneligliptin for the treatment of type 2 diabetes. Drugs Today (Barc). 2013;49:615–629.
   PubMed Web of Science ®Google Scholar